Abbott Laboratories plans to spin off its pharmaceutical unit in an attempt to command a higher valuation for its remaining businesses.

Under the plans, the company’s proprietary drug unit, responsible for approximately 45% of Abbott’s revenue, will be separated into a new company with publicly traded stock distributed to Abbott shareholders as a tax-fee transaction.

Richard Gonzalez will head the new unit, whereas the rest of Abbott – including diagnostics, devices, nutritional and branded-generic businesses – will retain the Abbott name.

The move comes after Abbott executives became worried that competitive threats for the company’s biggest selling drug, the anti-inflammatory Humira, were overshadowing separate Abbott businesses which were recording strong sales growth.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now